A randomized controlled trial of visible-light therapy for the prevention of oral mucositis

Sharon Elad; Noa Luboshitz-Shon; Tehila Cohen; Elad Wainchwaig; Michael Y. Shapira; Igor B. Resnick; Ruth Radiano; Rachel Lubart; Reuven Or

doi:10.1016/j.oraloncology.2010.11.013

A randomized controlled trial of visible-light therapy for the prevention of oral mucositis

Sharon Elad, Noa Luboshitz-Shon, Tehila Cohen, Elad Wainchwaig, Michael Y. Shapira, Igor B. Resnick, Ruth Radiano, Rachel Lubart, Reuven Or

Department of Chemistry

Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A VLT-device suitable for intra-oral use was applied to 20 patients undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. Oral mucositis was assessed using the OMAS and WHO scales. Oral pain and acceptance levels were scored by the patient using a 10-step scale. Patients were evaluated once a week until day 21 post-HSCT. Mucositis rate, severity and pain score were compared. At the third visit, 1 week post-HSCT, mucositis rates were significantly lower in the treatment group (for both WHO and OMAS p = 0.02). Mucositis was also less severe in the treatment group (for WHO p = 0.01; for OMAS p = 0.01). Furthermore, the patients in the treatment group reported lower pain levels (p = 0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of oral mucositis in patients undergoing HSCT.

Original language	English
Pages (from-to)	125-130
Number of pages	6
Journal	Oral Oncology
Volume	47
Issue number	2
DOIs	https://doi.org/10.1016/j.oraloncology.2010.11.013
State	Published - Feb 2011

Bibliographical note

Funding Information:
This study was supported by a grant from Qray Ltd . The authors wish to thank Dr. Mario Baras for his assistance with the statistical analysis and Ms. Amy Panzok and Mr. Scott Drucker for their help with English editing. Part of this study was presented in the DMD theses of Ms. Tehila Cohen and Mr. Elad Wainchwaig.

Funding

This study was supported by a grant from Qray Ltd . The authors wish to thank Dr. Mario Baras for his assistance with the statistical analysis and Ms. Amy Panzok and Mr. Scott Drucker for their help with English editing. Part of this study was presented in the DMD theses of Ms. Tehila Cohen and Mr. Elad Wainchwaig.

Funders	Funder number
Qray Ltd

Keywords

LLLT
Light
Low level laser therapy
Mucositis
Oral
Phototherapy
Prevention
Visible

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.oraloncology.2010.11.013

Cite this

@article{4ade8e48a78546a49d41399d9aaab15f,

title = "A randomized controlled trial of visible-light therapy for the prevention of oral mucositis",

abstract = "The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A VLT-device suitable for intra-oral use was applied to 20 patients undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. Oral mucositis was assessed using the OMAS and WHO scales. Oral pain and acceptance levels were scored by the patient using a 10-step scale. Patients were evaluated once a week until day 21 post-HSCT. Mucositis rate, severity and pain score were compared. At the third visit, 1 week post-HSCT, mucositis rates were significantly lower in the treatment group (for both WHO and OMAS p = 0.02). Mucositis was also less severe in the treatment group (for WHO p = 0.01; for OMAS p = 0.01). Furthermore, the patients in the treatment group reported lower pain levels (p = 0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of oral mucositis in patients undergoing HSCT.",

keywords = "LLLT, Light, Low level laser therapy, Mucositis, Oral, Phototherapy, Prevention, Visible",

author = "Sharon Elad and Noa Luboshitz-Shon and Tehila Cohen and Elad Wainchwaig and Shapira, \{Michael Y.\} and Resnick, \{Igor B.\} and Ruth Radiano and Rachel Lubart and Reuven Or",

note = "Funding Information: This study was supported by a grant from Qray Ltd . The authors wish to thank Dr. Mario Baras for his assistance with the statistical analysis and Ms. Amy Panzok and Mr. Scott Drucker for their help with English editing. Part of this study was presented in the DMD theses of Ms. Tehila Cohen and Mr. Elad Wainchwaig.",

year = "2011",

month = feb,

doi = "10.1016/j.oraloncology.2010.11.013",

language = "אנגלית",

volume = "47",

pages = "125--130",

journal = "Oral Oncology",

issn = "1368-8375",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - A randomized controlled trial of visible-light therapy for the prevention of oral mucositis

AU - Elad, Sharon

AU - Luboshitz-Shon, Noa

AU - Cohen, Tehila

AU - Wainchwaig, Elad

AU - Shapira, Michael Y.

AU - Resnick, Igor B.

AU - Radiano, Ruth

AU - Lubart, Rachel

AU - Or, Reuven

N1 - Funding Information: This study was supported by a grant from Qray Ltd . The authors wish to thank Dr. Mario Baras for his assistance with the statistical analysis and Ms. Amy Panzok and Mr. Scott Drucker for their help with English editing. Part of this study was presented in the DMD theses of Ms. Tehila Cohen and Mr. Elad Wainchwaig.

PY - 2011/2

Y1 - 2011/2

N2 - The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A VLT-device suitable for intra-oral use was applied to 20 patients undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. Oral mucositis was assessed using the OMAS and WHO scales. Oral pain and acceptance levels were scored by the patient using a 10-step scale. Patients were evaluated once a week until day 21 post-HSCT. Mucositis rate, severity and pain score were compared. At the third visit, 1 week post-HSCT, mucositis rates were significantly lower in the treatment group (for both WHO and OMAS p = 0.02). Mucositis was also less severe in the treatment group (for WHO p = 0.01; for OMAS p = 0.01). Furthermore, the patients in the treatment group reported lower pain levels (p = 0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of oral mucositis in patients undergoing HSCT.

AB - The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A VLT-device suitable for intra-oral use was applied to 20 patients undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. Oral mucositis was assessed using the OMAS and WHO scales. Oral pain and acceptance levels were scored by the patient using a 10-step scale. Patients were evaluated once a week until day 21 post-HSCT. Mucositis rate, severity and pain score were compared. At the third visit, 1 week post-HSCT, mucositis rates were significantly lower in the treatment group (for both WHO and OMAS p = 0.02). Mucositis was also less severe in the treatment group (for WHO p = 0.01; for OMAS p = 0.01). Furthermore, the patients in the treatment group reported lower pain levels (p = 0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of oral mucositis in patients undergoing HSCT.

KW - LLLT

KW - Light

KW - Low level laser therapy

KW - Mucositis

KW - Oral

KW - Phototherapy

KW - Prevention

KW - Visible

UR - https://www.scopus.com/pages/publications/79551690026

U2 - 10.1016/j.oraloncology.2010.11.013

DO - 10.1016/j.oraloncology.2010.11.013

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 21163686

AN - SCOPUS:79551690026

SN - 1368-8375

VL - 47

SP - 125

EP - 130

JO - Oral Oncology

JF - Oral Oncology

IS - 2

ER -

A randomized controlled trial of visible-light therapy for the prevention of oral mucositis

Abstract

Bibliographical note

Funding

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this